Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 2,289 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Clear all
Completed Phase 2 Interventional Results available

N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

NCT03759665
View directory record Official record
Conditions
GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 28, 2026, 10:50 PM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

NCT04271332
View directory record Official record
Conditions
16P11.2 Deletion Syndrome
Interventions
Arbaclofen, Placebo oral tablet
Drug
Lead sponsor
Clinical Research Associates, LLC
Other
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 28, 2026, 10:50 PM EDT
Recruiting Phase 2 Interventional

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

NCT05049057
View directory record Official record
Conditions
Posttraumatic Headache, Mild Traumatic Brain Injury
Interventions
Erenumab 140 Mg/mL Subcutaneous Solution, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Fort Bragg, North Carolina • Pittsburgh, Pennsylvania • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 1 Interventional

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

NCT01161836
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 28, 2026, 10:50 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

NCT07686081
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Ponesimod, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chula Vista, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 2 Interventional

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT01557777
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Navitoclax
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Pleasant Hill, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 28, 2026, 10:50 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Phase 3 Long-Term Safety Study of Migalastat

NCT01458119
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat hydrochloride
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
11
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 28, 2026, 10:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

NCT05938465
View directory record Official record
Conditions
Ileal Pouch
Interventions
EXE-346, Placebo
Biological · Other
Lead sponsor
Exegi Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

Open-label Treatment in Cushing's Syndrome

NCT03621280
View directory record Official record
Conditions
Cushing Syndrome, Cushing Disease
Interventions
Levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

NCT00411242
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
51
States / cities
Mesa, Arizona • Los Angeles, California • Oceanside, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 28, 2026, 10:50 PM EDT
Active, not recruiting Phase 3 Interventional

Pelacarsen Roll-over Extension Program

NCT06875973
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Pelacarsen (TQJ230)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
83
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

NCT01775618
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
Up to 12 Years · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 28, 2026, 10:50 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT04592341
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 4 Interventional Results available

Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care

NCT01893827
View directory record Official record
Conditions
Alcohol Dependence
Interventions
XR-NTX (Extended-Release Naltrexone), Oral Naltrexone (O-NTX)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 28, 2026, 10:50 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

NCT04708041
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 26 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
14
States / cities
Daly City, California • Oakland, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 28, 2026, 10:50 PM EDT
Active, not recruiting Phase 2 Interventional

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

NCT04053803
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
IMR-687
Drug
Lead sponsor
Imara, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Farmington, Connecticut • Hollywood, Florida • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 1 Interventional

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

NCT01149720
View directory record Official record
Conditions
Solid Tumors
Interventions
Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 28, 2026, 10:50 PM EDT
Terminated Phase 2 Interventional Results available

Atacicept in Multiple Sclerosis Extension Study, Phase II

NCT00853762
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Phoenix, Arizona • Northbrook, Illinois • East Lansing, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Lesinurad Monotherapy Extension Study in Gout

NCT01650246
View directory record Official record
Conditions
Gout
Interventions
lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

NCT00355641
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
59
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

NCT02963766
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 28, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects

NCT01691859
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 28, 2026, 10:50 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

NCT04641962
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
Bocidelpar, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
La Jolla, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 28, 2026, 10:50 PM EDT